MyMD and Rich 250 x 250 pxAre you interested in exploring cutting-edge autoimmune medicines? In this episode of BioTalk with Rich Bendis, we're delving deep into the world of transformative therapies with two remarkable guests, Dr. Chris Chapman and Dr. Adam Kaplin, from MyMD Pharmaceuticals. MyMD Pharmaceuticals is on a mission to make that a reality. Their lead clinical candidate, MYMD-1®, has the potential to reshape the entire field. But how does MYMD-1 work, and what sets it apart from current treatments? Join us as we unravel the science behind this revolutionary therapy and explore the potential indications and patient populations it could benefit. And that's not all. We also spotlight Supera-CBD, a novel synthetic cannabidiol with incredible potency and anti-inflammatory effects. How could this innovation change the landscape of chronic pain and anxiety management? Don't miss this episode of BioTalk with Rich Bendis as we embark on a journey into the future of autoimmune medicine with MyMD Pharmaceuticals. Tune in now and be part of the conversation.

Listen now via your favorite podcasting platform:

Click here to read the transcript.

Dr. Chapman is currently president, director, and chief medical officer at MyMD Pharmaceuticals and is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials. Prior to joining MyMD and since 1999, Dr. Chapman has operated Chapman Pharmaceutical Consulting, Inc., an organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues.

He is also the founder of Chapman Pharmaceutical Health Foundation, a nonprofit organization established to solicit public funds and support healthcare needs such as AIDS, diabetes, hypertension, lupus, sickle cell anemia, malaria and tuberculosis.

Dr. Chapman’s career includes executive leadership positions with Organon Pharmaceuticals and Quintiles (now known as IQVIA), board service for Rock Creek Pharmaceuticals, Inc. He also spent two years as a critical care physician on staff at Doctor's Community Hospital in Lanham, Maryland.

Dr. Chapman received his M.D. degree from Georgetown University in Washington, D.C. in 1987. He completed his internship in internal medicine, a residency in anesthesiology and a fellowship in cardiovascular and obstetric anesthesiology at Georgetown.

Prior to his time at Georgetown, Dr. Chapman served in the United States Air Force as a B-52 crew chief in the Vietnam era. Dr. Chapman has served at the Ellsworth Air Force Base in South Dakota, Andersen Air Force Base in Guam; U-Tapao Royal Thai Navy Base in Thailand; and Kadena Air Base in Japan.

Dr. Chapman is a graduate of the Harvard Kennedy School, Cambridge, Massachusetts, in financial management (2020).

Adam Kaplin, M.D., Ph.D., is the Chief Scientific Officer of MyMD, a role he assumed in December 2020.  Prior to joining MyMD, Dr. Kaplin held a number of positions at Johns Hopkins University, including the university’s Multiple Sclerosis Center of Excellence, Ketamine Clinic, and the School of Medicine’s Departments of Pyschiatry and Neurology.

Dr. Kaplin’s research focuses on the biological basis of immune mediated depression and cognitive impairment, using multiple sclerosis (MS) as a model. He is also active in applying health information technology to mental health, combining his work with neuropsychiatric consultation and ongoing care of patients with MS spectrum disorders.

His original research has been published more than 40 times in several different publications.  He is also the author or co-author of numerous review articles and textbooks. Dr. Kaplin graduated cum laude from Yale University in 1988, with a B.S. in biology.  He received his M.D. and Ph.D. from Johns Hopkins University in 1996.